Ask AI
ProCE Banner Activity

FAQs: An Oncology Nurse’s Perspectives on the Management of Adverse Events Associated With CDK4/6 Inhibitor Use for Patients With HR+/HER2- Breast Cancer

Clinical Thought

In this commentary, an oncology nurse addresses questions regarding optimal approaches for the management of adverse events associated with CDK4/6 inhibitors for patients with HR+/HER2- breast cancer, including ways to address barriers to meeting treatment goals and the importance of using a multidisciplinary team approach to achieve optimal outcomes.

Released: October 16, 2025

Share

Provided by

Provided by Clinical Care Options, LLC.

ProCE Banner

Supporters

Supported by an educational grant from Novartis Pharmaceuticals Corporation.

Novartis Pharmaceuticals Corporation

Faculty Disclosure

Primary Author

Ashley Martinez, DNP, APRN, FNP-BC, AOCNP, CPHQ, NEA-BC, NPD-BC: consultant/advisor/speaker: Biotheranostics, Curio Science, Lilly.